Core Viewpoint - Processa Pharmaceuticals, Inc. is participating in the 2025 BIO CEO & Investor Conference, highlighting its focus on developing next-generation cancer therapies with improved efficacy and safety [1][2]. Company Overview - Processa is a clinical-stage pharmaceutical company dedicated to developing Next Generation Cancer (NGC) drugs that modify existing FDA-approved oncology therapies to enhance their metabolism and distribution while preserving their cancer-killing mechanisms [3]. - The company's strategy combines a novel oncology pipeline with proven active molecules and a Regulatory Science Approach to create more effective and tolerable therapy options for cancer patients [3]. Conference Participation - Management will present a corporate overview on February 11, 2025, at 10:00 a.m. Eastern time and will engage in one-on-one meetings with registered investors throughout the conference [2].
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference